Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors

被引：12
|
作者：
Lee, Sung-Hyung
Chu, Seung Y.
Rashid, Rumana
Phung, Sheryl
Leung, Irene W.
Muchhal, Umesh S.
Moore, Gregory L.
Bernett, Matthew J.
Schubbert, Suzanne
Ardila, Connie
Bonzon, Christine
Foster, Paul
Szymkowski, David E.
Desjarlais, John R.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3633
引用
收藏
页数：2
相关论文
共 33 条
  • [1] Immunotherapy with anti-PSMA x anti-CD3 bispecific antibody stimulates potent killing of a human prostate cancer cell line and target mediated T cell activation in monkeys: A potential therapy for prostate cancer
    Chu, Seung Y.
    Pong, Erik W. K.
    Rashid, Rumana
    Chen, Hsing
    Chan, Emily W.
    Phung, Sheryl
    Endo, Nancy A.
    Ardila, Maria C.
    Bonzon, Christine
    Leung, Irene W. L.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Bernett, Matthew J.
    Desjarlais, John R.
    Szymkowski, David E.
    CANCER RESEARCH, 2016, 76
  • [2] Immunotherapy with Long-Lived Anti-CD38 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+Cells in Monkeys: A Potential Therapy for Multiple Myeloma
    Chu, Seung Y.
    Miranda, Yvonne
    Phung, Sheryl
    Chen, Hsing
    Rashid, Rumana
    Endo, Nancy A.
    Chan, Emily W.
    Pong, Erik
    Bonzon, Christine
    Muchhal, Umesh S.
    Leung, Irene W. L.
    Bernett, Matthew J.
    Moore, Gregory L.
    Szymkowski, David E.
    Desjarlais, John R.
    BLOOD, 2014, 124 (21)
  • [3] The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer
    Zhao, Huijun
    Ma, Juan
    Lei, Ting
    Ma, Wanru
    Zhang, Man
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (05) : 810 - 817
  • [4] Immunotherapy with Long-Lived Anti-CD20 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias
    Chu, Seung Y.
    Lee, Sung-Hyung
    Rashid, Rumana
    Chen, Hsing
    Chan, Emily W.
    Phung, Sheryl
    Pong, Erik
    Endo, Nancy A.
    Miranda, Yvonne
    Bonzon, Christine
    Leung, Irene W. L.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Bernett, Matthew J.
    Szymkowski, David E.
    Desjarlais, John R.
    BLOOD, 2014, 124 (21)
  • [5] Immunotherapy with Long-Lived Anti-CD123 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD1 23+Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia
    Chu, Seung Y.
    Pong, Erik
    Chen, Hsing
    Phung, Sheryl
    Chan, Emily W.
    Endo, Nancy A.
    Rashid, Rumana
    Bonzon, Christine
    Leung, Irene W. L.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Bernett, Matthew J.
    Szymkowski, David E.
    Desjarlais, John R.
    BLOOD, 2014, 124 (21)
  • [6] Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo
    Juan Ma
    Tengfei Shang
    Pan Ma
    Xin Sun
    Jin Zhao
    Ximing Sun
    Man Zhang
    Investigational New Drugs, 2019, 37 : 1036 - 1043
  • [7] Affinity tuned Xmab®2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells
    Zeng, Veronica G.
    Faber, Matthew S.
    Bernett, Matthew J.
    Avery, Kendra N.
    Zeytounian, John L.
    Rashid, Rumana
    Muchhal, Umesh S.
    Moore, Gregory L.
    Desjarlais, John R.
    Hedvat, Michael
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo
    Ma, Juan
    Shang, Tengfei
    Ma, Pan
    Sun, Xin
    Zhao, Jin
    Sun, Ximing
    Zhang, Man
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (05) : 1036 - 1043
  • [9] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody I:: Anti-tumor activity and survival in SCID/Beige mice.
    Smith, JA
    Davol, PA
    Kouttab, NM
    Rathore, R
    Elfenbein, GJ
    Lum, LG
    BLOOD, 2002, 100 (11) : 673A - 673A
  • [10] Combining anti-CD3 activated T cells armed with anti-CD3 x anti-Her2 bispecific antibody may provide an additional anti-tumor effect after stem cell transplant for breast cancer.
    Sen, M
    Wankowski, DM
    Lum, LG
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 743 - 743
1234